Acromegaly in elderly people;Acromégalie du sujet âgé

Annales d'Endocrinologie

Volumn 66, Issue 6, 2005, Pages 540-544

  Desailloud, R ^a   Crepin Hemon S ^a   Simovic Corroyer, B ^b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acromegaly; Elderly people

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; AGING; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; HEART DISEASE; HISTOPATHOLOGY; HUMAN; MORBIDITY; MORTALITY; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 29144487194     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4266(05)82115-8     Document Type: Short Survey

References (32)

1. Abs RV, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998 ; 83 : 374-378.
2. Affssaps. Prise en charge thérapeutique du patient dyslipidémique in Recommandations de Bonne Pratique, Agence Française de Sécurité Sanitaire des Produits de Santé, Affssaps 2005 ; 1-65.
3. Beers M. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med 1997 ; 157 : 1531-1537.
4. Campbell PR. Population Projections of the U.S. by Age, Sex, Race, and Hispanic Origin: 1993 to 2020 in Current Population Reports. U. G. P. Office. Washington, DC: 1994 ; 25-1111.
5. Chanson P,Timsit J, Masquet C et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990 ; 113 : 921-925.
6. Colao A, Amato G, Pedroncelli AM et al. Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 2002 ; 25 : 532-538.
7. Colao A, Cuocolo A, Marzullo P et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999 ; 84 : 17-23.
8. Colao A, Cuocolo A, Marzullo P et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 1999 ; 84 : 1518-1523.
9. Colao A, Merola B, Ferone D, Lombardi G. Extensive personal experience: acromegaly. J Clin Endocrinol Metab 1997 ; 82 : 2777-2781.
10. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol 2004 ; 151 : S93-S101.
11. Curtis L, Ostbye T, Sendersky V et al. Inappropriate prescribing for elderly americans in a large outpatient population. Arch Intern Med 2004 ; 164 : 1621-1625.
12. Ezzat S, Snyder PJ, Young WF et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992 ; 117 : 711.
13. Fick D, Cooper JW, Wade WE, Waller JL, Maclean R, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 ; 163 : 2716-2724.
14. Growth Hormone Research Society, Pituitary Society. Consensus Statement. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society. J Clin Endocrinol Metab 2004 ; 89 : 3099-3102.
15. Hermaann B, Bruch C, Sailer B et al. Occurence of ventricular late potentials in patients with active acromegaly. Clinical Endocrinology 2001 ; 55 : 201-207.
16. Herrington AM, George KW; Moulds CC. Octreotide-induced bradycardia. Pharmacotherapy 1998 ; 18 : 413-416.
17. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004 ; 89 : 667-674.
18. Juul AM, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF-1) and the IGF binding proteins (IGFBP-1,2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clinical Endocrinology. 1994 ; 41 : 85-93.
19. Lamberts SW, van der, Lely AJ, de Herder, WW, Hofland, LJ. Octreotide. N Engl J Med 1996 ; 334 :246.
20. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-1 decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002 ; 25 : 971-976.
21. Matta M, Caron P. Acromegalic cardiomyopathy: a review of the literature. Pituitary 2003 ; 6 : 203-207.
22. McLeod JP, Huan AR, Tamblyn RM. Defining inappropriate practices in prescribing for elderly people : a national consensus panel. CMAJ 1997 ; 156 : 385-391.
23. Minniti G, Jaffrain-Rea ML, Moroni,C et al. Echocardiographic evidence for a direct effect of GH/IGF1 hypersecretion on cardiac mass and function in young acromegalics. Clinical Endocrinology 1998 ; 49 : 101-106.
24. Minniti G, Moroni , Jaffrain-Rea ML et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Edocrinol (Oxf) 2001 ; 55: 307-313.
25. Parkinson C, Renehan AG, Ryder WDJ, O'Dwyer ST, Shalet SM, Trainer PJ. Gender and age influence the relationship between serum GH and IGF-1 in patients with acromegaly. Clinical Endocrinology 2002 ; 57 : 59-64.
26. Pereira A, van Thiel SW, Lindner JR et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004 ; 89 : 71-75.
27. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Edocrinol (Oxf) 1994 ; 41 : 95-102.
28. Richardson J, Cocanour CS, Kern JA et al. Perioperative assessment in elderly and high-risk patients. J Am Coll Surgeons 2004 ; 199 : 133-146.
29. Shepherd J, Blauw GJ, Murphy M.B et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 ; 360 : 1623-1630.
30. Trouillas J, Sassolas MP, Guignard P, Fonlupt P, Ansaneli-Naves L, Perrin G. Relationships between pathological diagnosis and clinical parameters in acromegaly. Metabolism 1996 ; 45 : 53-56.
31. van der Lely AH, Harrist AG, Lamberts SWJ. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clinical Endocrinology 1992 ; 37 : 181-185.
32. Webster J, Piscitelli MD, Polli A, Ferrarri CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994 ; 331 : 904-909.